Thomson Reuters Study Confirms Economic Viability of Orphan Drugs Repositioned for Unmet Medical Needs
(Thomson Reuters ONE) -
Orphan drugs achieve blockbuster status in 2011 and generate over $50 billion in
revenue
PHILADELPHIA, PA, August 22, 2012 - The Intellectual Property & Science business
of Thomson Reuters, the world's leading provider of intelligent information for
businesses and professionals, today released the results of its study on orphan
drugs, developed to treat rare diseases, finding that they have the potential to
generate as much lifetime revenue as drugs used for more common health
conditions. The findings are featured in the Thomson Reuters paper, "The
Economic Power of Orphan Drugs" and in Drug Discovery Today. Rare diseases
affect from a handful to up to 200,000 patients and include illnesses such as
Cystic fibrosis, Wilson's disease, and Homozygous familial hypercholesterolemia.
Life Sciences researchers at Thomson Reuters found that developmental drivers
such as government incentives, shorter clinical trials and high rates of
regulatory success make top orphan drugs as economically viable as non-orphan
ones, even though the number of patients benefitting from them is significantly
smaller than those benefitting from non-orphan medicine.
"This new data gives economic validity to the importance of targeting rare
diseases in the global pharmaceutical market," said Kiran Meekings, Ph.D., Life
Sciences consultant at Thomson Reuters and co-author of the report. "Not only
does such focus help those affected by rare diseases, of which there are 25
million people in the United States alone, it also furthers the aim of precision
medicine and substantiates the envisioned high returns on the R&D investment,
particularly for drugs with multiple orphan disease approvals."
Current estimates indicate that 250 new rare diseases are identified annually.
This report provides extensive and tangible evidence that orphan drug
development is an important component of biopharmaceutical R&D strategy and that
a number of orphan drug therapies are already achieving blockbuster status.
"The higher value of companies that have a strong orphan-drug strategy reflects
the increasing degree of optimism for the sale-and-profit potential of the rare
disease market," said Brian Lester, senior analyst and managing director of the
life sciences group at the financial services firm Manning & Napier. "We expect
the orphan disease business model to sustain a competitive edge over the
traditional primary care business model in the future."
The data was aggregated by Thomson Reuters Life Sciences consultants who
performed an economic analysis of orphan versus non-orphan drugs while
collaborating closely with Cory Williams, MD, Ph.D., Pfizer, in reporting their
findings.
Thomson Reuters compared the total value of orphan drugs from 1990 to 2030,
using its vast information solutions including Thomson Reuters Cortellis(TM),
Integrity and Newport Premium(TM), while industry benchmarking data was provided
by CMR International, a Thomson Reuters business and industry leader in global
R&D pharmaceutical measurement. This comprehensive information spans multiple
disciplines and supports the drug research and development lifecycle.
Read the full Thomson Reuters report: "The Economic Power of Orphan Drugs." View
"Orphan Drug Development: An Economically Viable Strategy for BioPharma R&D,"
the peer-reviewed article featured in Drug Discovery Today. Access the
infographic on the economic viability of orphan drugs. To learn more about
Thomson Reuters Life Sciences Professional Services, Integrity, Forecast, CMR
International and Newport Premium visit: http://ip-science.thomsonreuters.com/.
ABOUT THOMSON REUTERS
Thomson Reuters is the world's leading source of intelligent information for
businesses and professionals. We combine industry expertise with innovative
technology to deliver critical information to leading decision makers in the
financial and risk, legal, tax and accounting, intellectual property and science
and media markets, powered by the world's most trusted news organization. With
headquarters in New York and major operations in London and Eagan, Minnesota,
Thomson Reuters employs approximately 60,000 people and operates in over 100
countries. For more information, go to www.thomsonreuters.com.
CONTACT
Laura Gaze
Thomson Reuters
+1 203 868 3340
laura.gaze(at)thomsonreuters.com
Jen Breen
Thomson Reuters
+1 215 823 1791
jennifer.breen(at)thomsonreuters.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Thomson Reuters Corporation via Thomson Reuters ONE
[HUG#1635432]
Unternehmensinformation / Kurzprofil:
Datum: 22.08.2012 - 13:31 Uhr
Sprache: Deutsch
News-ID 176810
Anzahl Zeichen: 5498
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 182 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Thomson Reuters Study Confirms Economic Viability of Orphan Drugs Repositioned for Unmet Medical Needs"
steht unter der journalistisch-redaktionellen Verantwortung von
Thomson Reuters Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
